Kimberly J. Manhard's most recent trade in Inhibrx Biosciences Inc. was a trade of 15,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. | Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Inhibrx Biosciences Inc. | Kimberly J. Manhard | Director | Purchase of securities on an exchange or from another person at price $ 13.98 per share. | 28 Aug 2024 | 10,000 | 10,000 | - | 14.0 | 139,800 | Common Stock |
| Inhibrx Biosciences Inc. | Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Heron Therapeutics Inc | Kimberly J. Manhard | EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 4,564 | 29,747 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 4,564 | 27,936 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. | 13 Apr 2023 | 1,417 | 28,330 (0%) | 0% | 2.9 | 4,081 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,250 | 7,500 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,250 | 25,183 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 149,365 | 149,365 | - | - | Performance Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,564 | 32,500 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,564 | 25,945 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 13 Jan 2023 | 2,012 | 23,933 (0%) | 0% | 3.2 | 6,378 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Other type of transaction at price $ 3.27 per share. | 13 Jan 2023 | 1,655 | 20,131 (0%) | 0% | 3.3 | 5,416 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,250 | 8,750 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,250 | 21,381 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 4,564 | 37,064 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 4,564 | 20,488 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 13 Oct 2022 | 2,012 | 18,476 (0%) | 0% | 3.8 | 7,565 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,250 | 10,000 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,250 | 15,924 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 165,961 | 165,961 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 4,564 | 41,628 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 4,564 | 16,686 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 13 Jul 2022 | 2,012 | 14,674 (0%) | 0% | 3.0 | 6,056 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,250 | 12,122 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,250 | 11,250 | - | - | Restricted Stock Units | |
| Inhibrx Inc | Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 15,000 | 50,759 | - | - | Stock Option (right to buy) | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Sale of securities on an exchange or to another person at price $ 4.76 per share. | 03 May 2022 | 1,504 | 10,872 (0%) | 0% | 4.8 | 7,154 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Other type of transaction at price $ 3.84 per share. | 03 May 2022 | 1,504 | 12,376 (0%) | 0% | 3.8 | 5,778 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 4,564 | 12,884 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 4,564 | 46,192 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. | 13 Apr 2022 | 2,012 | 10,872 (0%) | 0% | 6.1 | 12,213 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,250 | 12,500 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,250 | 8,320 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 4,564 | 9,082 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 4,564 | 50,756 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. | 13 Jan 2022 | 2,012 | 7,070 (0%) | 0% | 8.3 | 16,700 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,250 | 13,750 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,250 | 4,518 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 92,200 | 92,200 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 55,320 | 55,320 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 1,250 | 3,701 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 1,250 | 15,000 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. | 13 Oct 2021 | 433 | 3,268 (0%) | 0% | 10.5 | 4,568 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 1,250 | 2,884 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 1,250 | 16,250 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. | 13 Jul 2021 | 433 | 2,451 (0%) | 0% | 13.5 | 5,837 | Common Stock |
| Inhibrx Inc | Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 15,000 | 35,759 | - | - | Stock Option (right to buy) | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Sale of securities on an exchange or to another person at price $ 17.66 per share. | 03 May 2021 | 1,529 | 1,634 (0%) | 0% | 17.7 | 27,009 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Other type of transaction at price $ 13.90 per share. | 03 May 2021 | 1,529 | 3,163 (0%) | 0% | 13.9 | 21,249 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 1,250 | 17,500 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 1,250 | 2,067 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. | 13 Apr 2021 | 433 | 1,634 (0%) | 0% | 16.7 | 7,214 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 1,250 | 1,250 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 1,250 | 18,750 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. | 13 Jan 2021 | 433 | 817 (0%) | 0% | 18.2 | 7,863 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. | 22 Dec 2020 | 10,000 | 10,000 (0%) | 0% | 13 | 130,000 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 10,000 | 48,416 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 22 Dec 2020 | 10,000 | 0 (0%) | 0% | 20 | 200,000 | Common Stock |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 120,000 | 120,000 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| Inhibrx Inc | Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2020 | 17,259 | 17,259 | - | - | Common Stock |